An experimental nasal vaccine provided strong protection against Covid infection, according to preliminary results from a Phase 1 clinical trial.
The vaccine, developed by a startup called Blue Lake Biotechnology Inc., was found to reduce the risk of symptomatic Covid infections by 86% for three months in people who received it as a booster dose.
Existing booster shots in the United States reduce symptomatic infections by 43% in people 18 to 49 over one to two months, according to a study published in November by the Centers for Disease Control and Prevention.
The results from the clinical trial offer an early but tantalizing glimpse at how a next-generation Covid vaccine could be more effective at stopping the coronavirus in its tracks.
Scientists have said nasal vaccines could provide better protection against Covid compared to those that are injected into the arm.
Source:Â NBC
© CopyRights RawNews1st
